FIELD: biotechnology.
SUBSTANCE: invention relates to a chimeric antigen receptor which specifically binds to DLL3, a recovered polynucleotide coding it, as well as a vector and a cell containing said polynucleotide. Also disclosed is a composition and a bottle containing said cell. Invention also relates to a binding agent against DLL3, as well as to a composition containing same.
EFFECT: invention is effective for treating or preventing a condition associated with undesirable and/or elevated levels of DLL3.
59 cl, 16 dwg, 10 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATES OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS WITH RIFAMYCIN AND USE THEREOF | 2015 |
|
RU2731055C2 |
| MOLECULES TARGETING A TYPE III SECRETION SYSTEM | 2016 |
|
RU2759949C2 |
| INDUCIBLE CHIMERIC CYTOKINE RECEPTORS | 2019 |
|
RU2826155C2 |
| IMMUNOGLOBULIN WITH TANDEM FAB- FRAGMENTS AND ITS APPLICATION OPTIONS | 2017 |
|
RU2767329C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH AMYELOIS TRANSPOSASE | 2020 |
|
RU2814721C2 |
| INTEGRATION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC CELLS WITH TRANSPOSASE FROM ORYZIAS | 2020 |
|
RU2817770C2 |
